Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-05. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
The Normans had a profound effect on Irish culture and history after their invasion at Bannow Bay in 1169. Initially, the Normans maintained a distinct culture and ethnicity. Yet, with time, they came to be subsumed into Irish culture to the point that it has been said that they became "more Irish than the Irish themselves". The Normans settled mostly in an area in the east of Ireland, later known as the Pale, and also built many fine castles and settlements, including Trim Castle and Dublin Castle. The cultures intermixed, borrowing from each other's language, culture and outlook. Norman surnames still exist today. Names such as French, (De) Roche, Devereux, D'Arcy and Lacy are particularly common in the southeast of Ireland, especially in the southern part of County Wexford, where the first Norman settlements were established. Other Norman names, such as Furlong, predominate there. Another common Norman-Irish name was Morell (Murrell), derived from the French Norman name Morel. Names beginning with Fitz- (from the Norman for "son") usually indicate Norman ancestry. Hiberno-Norman surnames with the prefix Fitz- include Fitzgerald, FitzGibbons (Gibbons) as well as Fitzmaurice. Families bearing such surnames as Barry (de Barra) and De Búrca (Burke) are also of Norman extraction.
aminoglycosides (gentamicin, amikacin, tobramycin, but not kanamycin) quinolones (ciprofloxacin, levofloxacin, but not moxifloxacin) cephalosporins (ceftazidime, cefepime, cefoperazone, cefpirome, ceftobiprole, but not cefuroxime, cefotaxime, or ceftriaxone) antipseudomonal penicillins: carboxypenicillins (carbenicillin and ticarcillin), and ureidopenicillins (mezlocillin, azlocillin, and piperacillin). P. aeruginosa is intrinsically resistant to all other penicillins. carbapenems (meropenem, imipenem, doripenem, but not ertapenem) polymyxins (polymyxin B and colistin) monobactams (aztreonam) As fluoroquinolones are one of the few antibiotic classes widely effective against P. aeruginosa, in some hospitals, their use is severely restricted to avoid the development of resistant strains. On the rare occasions where infection is superficial and limited (for example, ear infections or nail infections), topical gentamicin or colistin may be used. For pseudomonal wound infections, acetic acid with concentrations from 0.5% to 5% can be an effective bacteriostatic agent in eliminating the bacteria from the wound. Usually a sterile gauze soaked with acetic acid is placed on the wound after irrigation with normal saline. Dressing would be done once per day. Pseudomonas is usually eliminated in 90% of the cases after 10 to 14 days of treatment.
An overview of the diversity and evolution of snake fangs. Snake VenomsUMich Orientation of Proteins in Membranes families/superfamily-55 - Calculated orientations of snake venom phospholipases A2 and myotoxins in the lipid bilayer. An untapped biochemical archive in natural history collections, study of venom components for new drugs. BioRxiv, May 22, 2026. doi: https://doi.org/10.64898/2026.05.22.727068 LD50's for most toxic venoms. Australian Venom Research Unit Archived 24 February 2015 at the Wayback Machine – a general source of information for venomous creatures in Australia. biomedcentral.com – Medicinal and ethnoveterinary remedies of hunters in Trinidad. reptilis.net – How venom works. snakevenom.net – Drying and storage of snake venom.
== History == In 1902, William Bayliss and Ernest Starling were studying how the nervous system controls the process of digestion. It was known that the pancreas secreted digestive juices in response to the passage of food (chyme) through the pyloric sphincter into the duodenum. They discovered (by cutting all the nerves to the pancreas in their experimental animals) that this process was not, in fact, governed by the nervous system. They determined that a substance secreted by the intestinal lining stimulates the pancreas after being transported via the bloodstream. They named this intestinal secretion secretin. This type of 'chemical messenger' substance is now called a hormone, a term coined by Starling in 1905. Secretin is frequently erroneously stated to have been the first hormone identified. However, British researchers George Oliver and Edward Albert Schäfer had already published their findings of an adrenal extract increasing blood pressure and heart rate in brief reports in 1894 and a full publication in 1895, making adrenaline the first discovered hormone.
Common adverse effects (2.4–42%) included agitation or irritability, tachycardia, hallucinations or delusions, confusion, pupil dilation, hypertension, drowsiness or lethargy, elevated creatine phosphokinase (CPK), nausea and vomiting, and others. Selected serious adverse effects included fever or hyperthermia in 3.8%, single seizure in 2.4%, coma in 1.4%, elevated creatinine in 1.4%, multiple seizures in 1.2%, rhabdomyolysis in 1.1%, respiratory depression in 0.9%, cardiac conduction disorder in 0.5%, and status epilepticus in 0.4%. There is a case report of severe neurological sequelae following a single typical recreational dose of LSD involving seizure and cardiorespiratory arrest. In general, psychedelics like LSD may rarely cause seizures in some individuals. The median lethal dose (LD50) of LSD in animals varies and is 50 to 60 mg/kg in mice, 16.5 mg/kg in rats, and 0.3 mg/kg in rabbits all given by injection. A well-known 1962 instance of an elephant named Tusko given 297 mg (~0.1 mg/kg) LSD by intramuscular injection proved fatal. These findings suggest that elephants may be much more sensitive to LSD in overdose than humans and other species. However, this instance has been mired in criticism and controversy due to miscalculation of LSD dose and concomitant post-LSD administration of promazine and pentobarbital. The experiment was repeated in two elephants with similar doses of LSD in 1984 without incident. Massive doses of LSD are largely managed by symptomatic treatments, and agitation can be addressed with benzodiazepines.
Sources: en.wikipedia.org
== End group removal == Controlled radical polymerization, namely reversible addition−fragmentation chain-transfer polymerization (RAFT), is a common method for the polymerization of acrylates, methacrylates and acrylamides. Usually, a thiocarbonate is used in combination with an effective initiator for RAFT. The thiocarbonate moiety can be functionalized at the R-group for end group analysis. The end group is a result of the propagation of chain-transfer agents during the free-radical polymerization process. The end groups can subsequently be modified by the reaction of the thiocarbonylthio compounds with nucleophiles and ionic reducing agents.
This was from the notion that depression was primarily due to norepinephrine deficits, partly based on the fact that drugs that relieve depression increase brain norepinephrine levels. To date, a great number of potent and selective and mixed norepinephrine reuptake inhibitors (NRIs) have been marketed as antidepressants. The first commercially available selective norepinephrine reuptake inhibitor (sNRI) was reboxetine (Edronax) and was developed as a first-line therapy for major depressive disorder. The selectivity of reboxetine for the norepinephrine transporter (NET) results in benign side effect profile because the drug is well tolerated. In the laboratories of Chemistry of Farmitalia Carlo Erba (Milan, Italy), reboxetine was synthesized according to the general method described by Melloni et al. In 1993 Kabi Pharmacia, Swedish based pharmaceutical giant, bought Farmitalian and in 2003 Pfizer bought Pharmacia. Atomoxetine (Strattera) is another potent and selective NRI which is also effective and well tolerated treatment for adults with ADHD. This drug was the first ADHD treatment to be specially approved for adult use. Studies showed that atomoxetine is a nonstimulant and carries negligible risk of abuse. This discovery was groundbreaking as a beneficial new treatment option for adults with ADHD, specially those patients at risk of substance abuse.
Centers for Disease Control: Obesity Data and Statistics American Obesity Treatment Association: Obesity Education and Statistics Archived February 28, 2021, at the Wayback Machine Contributors to Obesity | Tableau Public Archived January 3, 2015, at the Wayback Machine (infographic for the United States)
Paramagnetic Fluorescence Quenching, the allowance of new electronic states upon binding a paramagnetic metal atom Photoinduced Electron Transfer (PET), the blocking of a lower energy state due to the binding of a metal atom. Photoinduced Charge Transfer (PCT), the modulation of energy levels in a complex by charge transfer within a conjugated pi system. Fluorescence Resonance Energy Transfer (FRET), the transfer of an exciton from a donor to an acceptor, modulating the emission spectrum. Excimer/Exciplex formation, the formation of a state that is a hybrid of the ground and excited states. This has novel fluorescent properties. Chemodosimeters, complexes that undergo irreversible reactions with other species upon binding a metal to form new compounds with novel fluorescent spectra. Fluorophores are essential to some measurement of the metal binding event, and indirectly, metal concentration. There are many types, all with different properties that make them advantageous for different applications. Some work as small metal sensors completely on their own while others must be complexed with a subunit that can chelate or bind a metal ion. Rhodamine for example undergoes a conformation change upon the binding of a metal ion. In so doing it switches between a colorless, non-fluorescent spirocyclic form to a fluorescent, pink open cyclic form. Quinoline based sensors have been developed that form luminescent complexes with Cd(II) and fluorescent ones with Zn(II).
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.